FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/03/2023
Back to search
Official data from USPTO
INNOVO THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
07/03/2023
Classification
Registered
Trademark type
Combined
Nice classes
42
Filing date
02/23/2021
Registration date
03/07/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/07/2023
Last transaction
03/07/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
KR
Examiner
SEVERSON, JUSTIN
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a design of a blue shaded circle with a white design made up of five white lines originating from a white center circle. Each white line has a white circle at the end. there are three white circles between the white lines on the left side. To the right of the design is the term "INNOVO" in blue font above "THERAPEUTICS" in smaller blue font.
Holders and representatives
Holders
Innovo Therapeutics Inc.
Representatives
Cynthia A. Moyer Fredrikson & Byron, P.A.
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Research and development of synthetic pharmaceuticals; research and development of biopharmaceuticals; research and development of diagnostic kits; research and development of reagents for developing pharmaceuticals; medicine research; development and service of pharmaceutical research technology; research and development of gene therapy products and modified gene therapy products; research and development of transgenic animals and plants; consulting of nonclinical testing of pharmaceuticals; consulting in the field of clinical test for pharmaceuticals; research and development of pharmaceuticals and drugs; research of process development for producing synthetic drugs; research and development of functional cosmetics; none of the aforesaid services in relation to the medical fields of incontinenceincontinence treatmenturinary treatment and conditions and pelvic floor conditions
Publications
History of USPTO decisions and trademark events.
37 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/12/2023
FIMP
FINAL DISPOSITION PROCESSED
06/12/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/07/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/07/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
03/07/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
02/12/2023
GPNX
NOTIFICATION PROCESSED BY IB
12/21/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/20/2022
PUBO
PUBLISHED FOR OPPOSITION
12/20/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/30/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/30/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/30/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/16/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/11/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/11/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/11/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/09/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/21/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
09/21/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/11/2022
GNRT
NON-FINAL ACTION E-MAILED
04/11/2022
CNRT
NON-FINAL ACTION WRITTEN
04/11/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/02/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/02/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/02/2022
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
03/02/2022
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
01/21/2022
RFNT
REFUSAL PROCESSED BY IB
11/15/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/24/2021
RFRR
REFUSAL PROCESSED BY MPU
10/15/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/28/2021
CNRT
NON-FINAL ACTION WRITTEN
09/27/2021
DOCK
ASSIGNED TO EXAMINER
09/17/2021
MAFR
APPLICATION FILING RECEIPT MAILED
04/20/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/16/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/15/2021
Continuous trademark protection
Get notified about every new filing that threatens INNOVO THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.